{"id":"NCT02005471","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","officialTitle":"A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-17","primaryCompletion":"2017-05-08","completion":"2022-08-03","firstPosted":"2013-12-09","resultsPosted":"2018-10-01","lastUpdate":"2023-10-17"},"enrollment":389,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia"],"interventions":[{"type":"DRUG","name":"Bendamustine","otherNames":[]},{"type":"DRUG","name":"Venetoclax","otherNames":["GDC-0199, ABT-199"]},{"type":"DRUG","name":"Rituximab","otherNames":[]}],"arms":[{"label":"Bendamustine + Rituximab","type":"ACTIVE_COMPARATOR"},{"label":"Venetoclax + Rituximab","type":"EXPERIMENTAL"},{"label":"Bendamustine + Rituximab Crossover Substudy","type":"EXPERIMENTAL"},{"label":"Venetoclax + Rituximab Re-Treatment","type":"EXPERIMENTAL"}],"summary":"The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).","primaryOutcome":{"measure":"Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death","timeFrame":"Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)","effectByArm":[{"arm":"Bendamustine + Rituximab Main Study","deltaMin":88.7,"sd":null},{"arm":"Venetoclax + Rituximab Main Study","deltaMin":70.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":111,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","France","Germany","Hungary","Italy","Netherlands","New Zealand","Poland","Russia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["40009494","35829925","35605176","32986498","30523712","29562156","27233802"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":84,"n":188},"commonTop":["Neutropenia","Diarrhoea","Nausea","Fatigue","Upper respiratory tract infection"]}}